Fennec Pharmaceuticals Inc.
FRX.TO
TSX
06/30/2025 | 03/31/2025 | ||||
---|---|---|---|---|---|
Revenue | 10.30% | 10.42% | |||
Total Other Revenue | -- | -- | |||
Total Revenue | 10.30% | 10.42% | |||
Cost of Revenue | 159.25% | -44.25% | |||
Gross Profit | 3.66% | 15.46% | |||
SG&A Expenses | 24.40% | 11.70% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | 29.55% | 7.90% | |||
Operating Income | -238.12% | 13.49% | |||
Income Before Tax | -170.56% | 28.09% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | -170.56% | 41.31% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | -170.56% | 41.31% | |||
EBIT | -238.12% | 13.49% | |||
EBITDA | -246.16% | 13.97% | |||
EPS Basic | -169.91% | 41.63% | |||
Normalized Basic EPS | -169.70% | 25.21% | |||
EPS Diluted | -169.91% | 47.97% | |||
Normalized Diluted EPS | -169.70% | 25.21% | |||
Average Basic Shares Outstanding | 0.31% | 0.43% | |||
Average Diluted Shares Outstanding | 0.31% | 0.43% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |